Crinetics reported over $5M unaudited net product revenue for PALSONIFY in Q4 2025 with over 200 enrollment forms filed. Phase 2 atumelnant cohort 4 achieved a 67% mean reduction in androstenedione and enabled 88% of patients to taper glucocorticoids to physiologic levels, with no hepatic adverse events.